FDANews
FDAnews Drug Daily Bulletin

FDA Grounds Foshan Flying Medical Products

Aug. 29, 2017

The FDA warned a Chinese drugmaker for inadequate testing and quality control for drug supplies and finished products, as well as numerous other GMP violations.

The agency inspected Foshan Flying Medical Products, of Foshan City, Guangdong, in February and found the facility’s quality control unit failed to maintain change control records and other required documents.

The facility also failed to test each batch of drug product for conformance with specifications for the identity and strength of active ingredients, the agency said, in a warning letter.

View today's stories